Demodicosis as a Skin Complication in Organ Transplant Recipients: A Case Series

07 October 2022: Articles

Rare coexistence of disease or pathology

Adriana Marquardt-Feszler ^A* , Maria Alicja Dębska-Ślizień ^C , Beata Imko-Walczuk ^A

DOI: 10.12659/AJCR.936467

Am J Case Rep 2022; 23:e936467

Table 1. Characteristics of studied patients.

	Case 1	Case 2	Case 3	Case 4
Age and gender	79 M	64 M	70 M	68 M
Original kidney disease	Glomerulonephritis, DM2	Agenesis	DM1	Glomerulonephritis
Time since transplantation to diagnosis of demodicosis	10 years	6 years	8 years	6 years
Daily doses of immunosuppression	MMF – 250 mgTAC – 1 mgMP – 4 mg	TAC – 2 mgMP – 4 mg	MMF – 500 mgCsA – 125 mgP – 5 mg	MMF – 1500 mgTAC – 2 mgP – 5 mg
Skin type []²⁵	I	II	II	II
Diagnostic method	Microscopic evaluation of scrapings of the face
Type of skin lesions and symptoms	Itch, pustules, papules and telangiectasias	Itch, dryness and redness	Itch	Itch, burning, telangiectasias
Additional skin lesions	BCC, actinic keratosis, seborrheic keratosis	BCC	BCC, actinic keratosis	BCC, actinic keratosis, seborrheic keratosis
Treatment	TI 10 mg/g, TP 5%	TI 10 mg/g, TP 5%	TI 10 mg/g, TP 5%	TI 10 mg/g, TP 5%
Time of therapy to full resolution	8 weeks	8 weeks	16 weeks	8 weeks
BCC – basal cell carcinoma; CsA – cyclosporin A; DM1 – diabetes mellitus type 1; DM2 – diabetes mellitus type 2; DM – Demodex mites; M – male; MMF – mycophenolate mofetil; MP – methylprednisone; P – prednisone; TAC – tacrolimus; TI – topical ivermectin; TP – topical permethrin.